HOLX vs. QGEN, GEHC, COO, ALNY, GMAB, WAT, LH, AVTR, ILMN, and TEVA
Should you be buying Hologic stock or one of its competitors? The main competitors of Hologic include Qiagen (QGEN), GE HealthCare Technologies (GEHC), Cooper Companies (COO), Alnylam Pharmaceuticals (ALNY), Genmab A/S (GMAB), Waters (WAT), Laboratory Co. of America (LH), Avantor (AVTR), Illumina (ILMN), and Teva Pharmaceutical Industries (TEVA). These companies are all part of the "medical" sector.
Qiagen (NYSE:QGEN) and Hologic (NASDAQ:HOLX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, community ranking, risk and media sentiment.
Qiagen currently has a consensus target price of $50.95, suggesting a potential upside of 18.53%. Hologic has a consensus target price of $84.56, suggesting a potential upside of 10.47%. Given Hologic's stronger consensus rating and higher probable upside, equities research analysts clearly believe Qiagen is more favorable than Hologic.
Qiagen has a net margin of 17.38% compared to Qiagen's net margin of 11.78%. Qiagen's return on equity of 18.81% beat Hologic's return on equity.
In the previous week, Qiagen had 8 more articles in the media than Hologic. MarketBeat recorded 37 mentions for Qiagen and 29 mentions for Hologic. Qiagen's average media sentiment score of 0.49 beat Hologic's score of 0.41 indicating that Hologic is being referred to more favorably in the news media.
Hologic received 610 more outperform votes than Qiagen when rated by MarketBeat users. Likewise, 69.74% of users gave Hologic an outperform vote while only 60.79% of users gave Qiagen an outperform vote.
70.0% of Qiagen shares are owned by institutional investors. Comparatively, 94.7% of Hologic shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 1.8% of Hologic shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Hologic has higher revenue and earnings than Qiagen. Qiagen is trading at a lower price-to-earnings ratio than Hologic, indicating that it is currently the more affordable of the two stocks.
Qiagen has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500. Comparatively, Hologic has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500.
Summary
Hologic beats Qiagen on 11 of the 17 factors compared between the two stocks.
Get Hologic News Delivered to You Automatically
Sign up to receive the latest news and ratings for HOLX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HOLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
